Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 12.18 USD 0.83% Market Closed
Market Cap: 1.2B USD
Have any thoughts about
Intellia Therapeutics Inc?
Write Note

Wall Street
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 60.18 USD with a low forecast of 14.14 USD and a high forecast of 134.4 USD.

Lowest
Price Target
14.14 USD
16% Upside
Average
Price Target
60.18 USD
394% Upside
Highest
Price Target
134.4 USD
1 003% Upside

NTLA Last Price Targets
Intellia Therapeutics Inc

The latest public price target was made on Nov 11, 2024 by Jay Olson from Oppenheimer , who expects NTLA stock to rise by 393% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Jay Olson
Oppenheimer
60 USD
Upside 393%
1 month ago
Nov 11, 2024
Intellia Therapeutics (NTLA) PT Lowered to $60 at Oppenheimer
StreetInsider
Jack Allen
Robert W. Baird
18 USD
Upside 48%
1 month ago
Oct 24, 2024
Intellia Therapeutics (NTLA) PT Lowered to $18 at Baird
StreetInsider
Luca Issi
RBC Capital
54 USD
Upside 343%
4 months ago
Aug 9, 2024
Intellia Therapeutics (NTLA) PT Lowered to $54 at RBC Capital
StreetInsider
Dae Gon Ha
Stifel Nicolaus
80 USD
Upside 557%
5 months ago
Jun 24, 2024
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
StreetInsider
Jack Allen
Robert W. Baird
24 USD
Upside 97%
5 months ago
Jun 24, 2024
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
StreetInsider
Kostas Biliouris
BMO Capital
70 USD
Upside 475%
7 months ago
May 10, 2024
Intellia Therapeutics (NTLA) PT Raised to $70 at BMO Capital
StreetInsider
Unknown Analyst
Cantor Fitzgerald
67 USD
Upside 450%
1 year ago
Feb 1, 2023
Cantor Fitzgerald Initiates Coverage On Intellia Therapeutics with Overweight Rating, Announces Price Target of $67
Benzinga
Show More Price Targets
Show Less Price Targets
Jay Olson
Oppenheimer
Price Target 60 USD
Upside/Downside 393%
View Source
Jack Allen
Robert W. Baird
Price Target 18 USD
Upside/Downside 48%
View Source
Luca Issi
RBC Capital
Price Target 54 USD
Upside/Downside 343%
View Source
Dae Gon Ha
Stifel Nicolaus
Price Target 80 USD
Upside/Downside 557%
View Source
Jack Allen
Robert W. Baird
Price Target 24 USD
Upside/Downside 97%
View Source
Kostas Biliouris
BMO Capital
Price Target 70 USD
Upside/Downside 475%
View Source
Unknown Analyst
Cantor Fitzgerald
Price Target 67 USD
Upside/Downside 450%
View Source
Show More Price Targets
Show Less Price Targets
Intellia Therapeutics Inc Competitors:
Price Targets
MYGN
Myriad Genetics Inc
77% Upside
SRPT
Sarepta Therapeutics Inc
58% Upside
MAB
Mabion SA
38% Upside
2616
CStone Pharmaceuticals
8% Upside
DAWN
Day One Biopharmaceuticals Inc
195% Upside
SIGHT
Gensight Biologics SA
40% Upside
QNCX
Quince Therapeutics Inc
416% Upside
251120
Bio-FD&C Co Ltd
48% Upside

Revenue
Forecast

Revenue Estimate
Intellia Therapeutics Inc

For the last 8 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 91%.

25%
Past Growth
91%
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-49%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NTLA's stock price target?
Price Target
60.18 USD

According to Wall Street analysts, the average 1-year price target for NTLA is 60.18 USD with a low forecast of 14.14 USD and a high forecast of 134.4 USD.

What is Intellia Therapeutics Inc's Revenue forecast?
Projected CAGR
91%

For the last 8 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 91%.

Back to Top